Evidence map›Paper›PMID 34717625›Full record

ReviewCancer cell international2021

Resveratrol mediates its anti-cancer effects by Nrf2 signaling pathway activation.

Matin Alavi, Tahereh Farkhondeh, Michael Aschner, Saeed Samarghandian

Open access · goldAbstract readReview
In one paragraph

Review in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Correlative study ofFrontiers in microbiology · 2026
    Article
  10. Review
  11. Review
  12. Stilbene Glycosides inPlants (Basel, Switzerland) · 2025
    Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Matin AlaviFaculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Tahereh FarkhondehCardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Michael AschnerDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, Forchheimer 209, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.
Saeed SamarghandianNoncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran. samarghandians1@nums.ac.ir.ORCID http://orcid.org/0000-0001-5461-9579
Albert Einstein College of Medicine · USBirjand University of Medical Sciences · IRMashhad University of Medical Sciences · IRUniversity of Neyshabur · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AIM AND

backgroundCancer represents a major health problem with an exceedingly high toll on the patients, their families, and the economy. Cancers are also associated with high mortality rates. Existing therapies for cancer are generally ineffective with many side effects.

methodA search was conducted on Pubmed, Google Scholar, Scopus, and web of science databases, and articles related to anticancer effects of resveratrol were collected.

resultsResveratrol is a natural compound that can activate the Nrf2 transcription factor. Nfr2 translocates to the nucleus and induces antioxidant gene expression. In different cell lines, resveratrol can increase apoptosis and inhibit the proliferation of cancer cells.

conclusionWe found that resveratrol shows efficacy for the treatment of cancer, but due to high controversy on the Nrf2 signaling pathway and mechanisms of resveratrol action, additional studies should be conducted to better characterize its mode-of-action in cancer.

Indexed as

CancerNrf2Resveratrol

Identifiers

PMID34717625
PMCPMC8557610
OpenAlexW3208248640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.